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l Introduction
Beta-mimetic drugs are currently used in ob-
stetrics to treat several disorders: Threatened
premature labor, hyperdynamic labor, or acute
fetal distress [2, 5, 6, 7, 8, 12]. Nevertheless the
effectiveness o£ this treatment may be limited by
the fact that the Stimulation of the uterine re-
ceptors i s not specific and is accompanied by the
Stimulation of the other beta-receptors distributed
throughout the whole anatomy. For this reason,
the desirable Inhibition of the uterine activity is
accompanied by the appearance of the undesirable
side-effects. The most evident among them are
those related to the Stimulation of the cardiovascu-
lar beta-receptors (tachycardia, etc.). On the other
hand, the Stimulation of the metabolic beta-re-
ceptors, leads, äs can be exepted, to an jncrease in
the levels of blood glucose [8], 11.
By avoiding the cardiovascular and/ the
metabolic effects of these drugs they could be
used in those cases in which a preexisting pathol-
ogy (heart disease, diabetes, etc.) might result in a
serious deleterious Situation. In some normal
patients the need of high doses to obtain a
suitable uterine effect, could result in a greater
than usual development of the side-effects, thus
making it desirable in these normal patients to
supress them, at least> to some extent.
An ideal Situation would be the possibility of
obtaining specific stimulators for the receptor
sites of different organs. But, up to the present
time, nothing indicates a qualitative differentation
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among them. In consequence a specific uterine
beta-mimetic drug does not exist.
For this purpose of avoiding this difficulty,
ESKES et al. [4] in 1965 suggested the use of a
beta-blocker with the aim of obtaining a cardio-
specificity in the blockade, but for the reasons
mentioned above, the possible existence of a
site-specific blocker is also very doubtful. In
fact, working with isoproterenol MAHON et al.
[9] could not find the selectivity of beta-receptors
in vessels and uterus.
At this point, the only possibility of interfering
with the beta-mimetic effects at different levels
would be the existence of differences either
qualitative or quantitative in the competition
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between beta-mimetic and beta-blocker at the
receptor binding site of the different Organs.
This could explain the close relation existing
between the cardiospecificity of some beta-
blockers, claimed to be cardiospecific, and the
doses used. That is, when used at therapeutical
doses, they do not apparendy evoke extracardiac
effects, which appear only when the doses used
result in a Stimulation of the sites located in
other organs.
The purpose of the present study is the search
for a dose of a beta-blocker, being active at
cardiovascular level without impairing the
desired beta-mimetic effect at uterine level.
2 Material and methods
The present study was carried out on 12 patients in labor.
The criteria for admission to the study were the following:
38—42 weeks o£ a normal pregnancy, normal maternal
electrocardiogram, uterine activity over 100 Montevideo
Units (M. U.), cervical dilatation between 3 and 5 cm,
ruptured membranes, cephalic presentation, a period of
fasting of at least 8 hours, no medication before and
during the investigation, and no signs of fetal distress.
In all cases the following variables listed with the corre-
sponding methods were studied:
a) Intraamniotic pressure was registered using a
Teflon open-tip catheter transvaginally inserted in the
amniotic sac filled with saline and connecting its free end
to a STATHAM pressure transducer.
b) Maternal heart rate (MHR) was obtained with a
continuous cardiotachometric recorder, triggered by the
R wave of the maternal electrocardiogram obtained with
skin electrodes.
c) Maternal electrocardiogram (MECG) was also
continuously recorded.
d) Fetal heart rate (FHR) was obtained with a continuous
electrocardiotachometer triggered by the R wave of the
fetal electrocardiogram, using a scalp electrode.
The above variables were recorded with a BECKMAN
multichannel polygraph (R 4 II).
e) Maternal blood pressure was measured before,
during and after the infusion of the drugs to the mother,
using the indirect auscultatory method.
f) Fetal capillary pH. Fetal blood samples were obtained
before, during and after the infusion of the drugs to the
mother, by SALING'S technique [9] using previously
heparinized glass pipettes. The actual pH was determined
immediately after obtaining the samples with a glass
microelectrode (AsTR.up-RADIOMETER) .
g) Maternal pH of the antecubital venous blood was
determined before, during and after ,the infusion of the
drugs.
In some cases, äs indicated in the description of the study,
venous maternal and capillary fetal blood glucose levels
were also determined using the glucose-oxidase method.
The drugs used were: Ritodrine HC1*) äs beta-mimetic and
Practolol**) äs beta-blocker [l, 3]. The drugs were always
administered in saline.
3 Design of the study
The present study on the possible use of a beta-
mimetic drug in combination with a beta-blocker
can be divided into four successive stages, the
characteristics of each being determined by the
suggestions arising from the results obtained in
the preceding one.
3.1 Stage l
The first stage was ündertaken with the aim of
elucidating any kind of deleterious side-effects of
the administration of such a combination in-
volved. A continuous infusion of the beta-
mimetic drug at doses inducing evident maternal
tachycardia, (pulse rate 20% or more over the
previous values) was given to the mother.
During prolonged infusion, the beta-blocker was
infused on two different occasions. The maximum
dose of beta-mimetic used was 600 mcg/min and
the infusion lasted 60 minutes. The infusions of
the beta-blocker lasted 4 and 5 minutes and the
total dose was 10 mg. This scheme was used in
two cases.
3.2 Stage 2
Since no deleterious effects were recorded in
this first group, we went further with two
other patients in a second one, »trying to determine
the uterine activity and side-effects when the
beta-mimetic was used together with the same
dose of beta-blocker from the beginning, in the
belief that the action of the beta-blocker on the
uterine Inhibition could be impaired by the
great amount of beta-mimetic that reached the
receptors in the doses and time administered to
the first patients.
In order to test this effect the following scheme
was designed: Two infusions of the beta-mimetic
drug were given to every patient for two periods
of 13 and 10 minutes. The lagtime between the
*) Pre-Par® = DU-21220 (PHILIPS^DUPHAR, The
Netherlands).
**) Eraldin® = ICI-125 (ICI-FARMA, S. A., Spain).
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two infusions was the period necessary for
reaching the previous values in MHR and FHR.
The second infusion was accompained by an
infusion o£ beta-blocker at a dose of l mg/min.
In this group we measured the same variables s
in the first, but in addition, determinations of
fetal and maternal blood glucose were per-
formed before and after the administration of
each infusion.
3.3 Stage 3
The encouraging results obtained in this group,
particularly in respect to glucose levels in fetus
and mother suggesting a possible Inhibition of
the beta-mimetic effects, prompted us to continue
the investigation of the metabolic effects. In
order to Support these findings the second part of
the protocol described above was applied to six
other patients, using lower doses of the beta-
mimetic drug. It consisted of a continuous in-
fusion of the beta-mimetic (Ritodrine, 250 mcg/
min for 10 minutes) in combination with the
beta-blocker (Practolol, l mg/min for the same
time). The results showed a complete blockade of
the beta-mimetic effects, even the desired one
and suggested the possibility of an overdose of
the beta-blocker (only maternal and fetal glucose
showed a pattern of beta-mimetic effect).
3.4 Stage 4
To elucidate that point, we repeated the same
scheme on two other patients, but using a dose
of 0,5 mg/min, for the beta-blocker.
Since the results obtained in this last group do
not show a definite trend and might be considered
controversial, they will be discussed in the
"discussion" in more detail.
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Fig. 1. Case corresponding to the first group of the study. Administration of incrcasing doses of Ritodrine lead to the
typical efiects of the drug. The administration of the beta-blocker infusions modified the cardiovascular effects, but he
uterine activity did not resume.
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4 Results
4.1 Group l
As can be seen in Fig. l the administration of
increasing doses of Ritrodine (from 200 mcg/min
to 600 mcg/min), leads to the typical effects of the
drug, that is maternal tachycardia (from 90—
100 beats/min to 120—130 beats/min), fetal
tachycardia (from 130—140 beats/min to 150—
160 beats/min), slight increase in the maternal
blood pressure (from 35 mmHg to 40 mmHg)
and a complete Inhibition of the uterine mo-
tility. When the beta-blocker was given, the
maternal tachycardia decreased (from 134 beats/
min to 120 beats/min), specially for the first
administration. There was no significant modi-
fication in the maternal pressure. Twelve minutes
after the beginning of the first beta-blocker in-
fusion, FHR also decreased (from 155 beats/min to
130 beats/min). Lastly, the uterine activity did not
resume.
From the biochemical point of view we have not
observed significant changes in maternal and
fetal pH. On the other hand, no pathological
changes in the MECG were found. Concerning
these parameters, similar results were found in
the cases of all the groups,
4.2 Group 2
Fig. 2 shows the results of the second scheme of
treatment. The first Ritrodrine infusion produced
maternal tachycardia that rose from a previous
value of 88 beats/min to 118 beats/min, when
600 mcg/min of the beta-mimetic drug was
infused. Also a slight fetal tachycardia appeared
(from 124 beats/min to around 132 beats/min).
There was no change in the differential blood
pressure. Uterine motility was completely in-
hibited.
When the Ritodrine infusion was repeated in
combination with the Practolol infusion, MHR
did not increase äs previously. In fäct, it changed
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Fig. 2. When the combination of the beta-mimetic with the beta-blocker was given to the mother, the cardio-
vascular effects of the first drug were limited.
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Fig. 3. The beta-mimetic infusion produced a significant
increase in the maternal and fetal blood glucose, but when
the drug was given in combination with the beta-blocker
the glucose levels decreased.
from 92 beats/min to a maximum of 106 beats/
min. FHR, that had not returned to the values
recorded before the first Ritodrine infusion,
decreased considerably when the combination of
drugs was given to the mother (from 140 beats/
min to 118 beats/min). There was no modification
in maternal blood pressure and uterine motility
did not resume. It is necessary to say that in the
cases of this group, the second part of the scheme
was started before the uterine activity reached
its previous values.
Fig. 3 shows the results obtained in the blood
glucose levels in the mother and fetus. As can be
seen, the beta-mimetic infusion leads to an im:
portant increase in the two values (from 120 mg%
to 165 mg% in the mother, and from 80 mg% to
120 mg% in the fetus).
When the same dose of beta-mimetic drug was
given to the mother simultaneously with the
beta-blocker, the maternal and fetal blood glucose
decreased from 140 mg% to 130 mg% in the
mother, and from 120 mg% to 110 mg% in the
fetus.
4.3 Group 3
Fig. 4 shows the absence of the beta-mimetic
effect on MHR, FHR and uterine motility, when
the Ritodrine infusion was simultaneously given
to the mother with l mg/min of Practolol; that
is the blockade of the beta-mimetic effects.
Nevertheless, the typical increase in maternal
blood glucose induced by the beta-stimulation
appeared in 5 out of the six cases studied, äs
shown in Fig. 5 (mean previous value =
73.3 mg%; mean values 30, 60, 90 and 120 minutes
later = 82.0, 81.6, 80.0 and 91.3 mg% respec-
tively).
An increase in fetal blood glucose was found in
all cases, äs shown in Fig. 6 (mean previous value
52.6 mg%; mean values 30, 60, 90 and 120 mi-
nutes later = 61.0, 64.8, 77.2 and 83.3 mg%
respectively).
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Fig. 4. The combination pf clini-
cal doses of Ritodrine (250 mcg/
min) with l mg/min of Practolol
lead to a complete blockade of
the beta-mimetic effects on MHR,
FHR and uterine motility.
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Fig. 5. The combination of clinical doses of Ritodrine
(250 mcg/min) with l mg/min of Practolol lead to the
typical increase in maternal blood glucose induced by the
beta-stimulation, in 5 out of the 6 cases studied. Individual
values.
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Fig. 6. The combination of 250 mcg/min of Ritodrine
with l mg/min of Practolol lead to typical increase in fetal
blood glucose induced by the beta-stimulation. Individual
values.
Fig. 7. First case from group 4th in which
the combination of 250 mcg/min .of Rito-
drine with 0,5 mgof Practolol was given to
the mother. The desirable effects appeared.
That is no maternal and fetal tachycardia
and Inhibition of the uterine motility.
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4.4 Group 4
In one case (Fig. 7), during the infusion of the
drug combination the uterine motility was
inhibited (uterine activity before the infusion =
106.6 M. U.; uterine activity during the in-
fusion = 30.0 M. U.; Inhibition 64.7%).Maternal
and fetal tachycardia did not appear and maternal
blood glucose did not showan important increase
from the previous value during the first 60 mi-
nutes (73 mg% before the infusion and 74 and
75 mg%, 30 and 60 minutes later), but rose to
100 mg% in 90 minutes.
In contrast, fetal blood glucose rose after the
infusion (61 mg% before the infusion and 76,
84 and 73 mg% 30, 60, 90 minutes. later).
Also in the other case, neither maternal of fetal
heart rate showed tachycardia, with no evaluable
change in the maternal blood glucose (65 mg%
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before the Infusion, 66 mg% 30, 60 and 90 before the infusion and 63, 61, 65 and 61mg%
minutes later, and 73mg% 120 minutes later), 30, 60, 90 and 120 minutes later), but uterine
fetal blood glucose rose after the infusion (55mg% motility failed to be inhibited (Fig. 8 and 9).
Fig. 8. Second case from the group
4 in which also the combination
of 250 mcg/min of Ritodrine with
0,5 mg/min of Practolol was given
to the mother. In that case the
uterine activity did not show the
effect of the beta-stimulation.
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Fig. 9. Maternal and fetal blood glucose corresponding to
the cases showed in Figs. 7 and 8. As can be seen, maternal
blood glucose did not modify but fetal blood glucose
increased under the effect of the drugs administered to the
mother.
5 Discussion
As can be seen, the plan of the study has been
rather unusual äs the eifects studied are in the
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Time [minj
obstetrical field. In fact, the association of a
beta-mimetic and a beta-blocker might appear
some what illogicaL Since 1968, some articles
[l, 3] have been published in claiming the cardio-
specificity of certain beta-blocker agents. Although
from these studies it was clear that this so-called
cardiospecificity was mainly a "cardiopreference",
it seemed interesting to us to give a new chance
to the ESKES idea of blocking undersirable beta-
mimetic eifects in the use of these drugs in
obstetrics.
For this reason the two first schemes were
designed. The unusual high doses of beta-
mimetic used in these schemes, may seem sur-
prising but we believed that if the selectivity of
the beta-blocker existed it would be also apparent
in those doses. Since -the beta-blocker can be a
dangerous drug, it seemed safer to combine its
use with its liatural antagonist which, when used
in those doses, could prevent any kind of dan-
gerous effect. In fact, äs expected, the administra-
tion of the beta-blocker could counteract the
beta-mimetic eifects to some extent without
impairing its uterine Inhibition. These findings
emphasised further the "cardiopreference" that
gave rise to the study. Nevertheless, the two cases
of the second treatment scheme showed that the
120
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beta-blocker was capable of Inhibition. On the
other hand, the fact that maternal and fetal blood
glucose did not show the usual increase due to
the beta-mimetic action, prompted us to continue
the study.
When \ve tried to use the same doses of beta-
blocker with clinical doses of the betamimetic
drug we saw an almost complete disappearence
of the beta-mimetic effects. Meanwhile, maternal
and fetal heart rate maintained the normal values;
in spite of the beta-mimetic infusion, the uterine
activity (the main objective of the beta-mimetic
treatment) was not inhibited. However, the
metabolic eflfects of the beta-stimulation did not
fail to appear.
These results lead to the conclusion that this
dose of beta-blocker was able to compete at the
level of cellular receptors with the beta-mimetic
drug to an extent that overwhelmed this assumed
preference. The logical inference was the need of
decreasing the beta-blocker doses.
When with the same patient we used a dose of
the blocker which was half that of the previous
one, the hypothesis seemed to be confirmed.
In fact in that case we obtained a desirable
uterine Inhibition without maternal and/or
fetal tachycardia. On the other hand maternal
blood glucose did not change and only fetal
blood glucose showed the beta-mimetic effect.
That could be due to a lagtime in the effects of
the beta-blocker administration to the fetus, and
establish the proof of the possibility of a single
metabolic response by the fetus to the beta-
mimetic treatment without maternal Variation in
blood glucose.
When this .experience was repeated in a second
case all parameters behaved similarly, except
uterine activity which was not inhibited. This
raises the problem of individual responses.
Since we are working with the competition at
receptor level, the threshold between partial and
total competition has to be very slight. For this
reason an adequate dose, established indi-
vidually, would be necessary in the use of
these drugs, and need to be investigated. How-
ever, another mechanism of action in the effect
of the beta-blocker can not be excluded since its
administration can impair the beta-mimetic
effects obtained by the direct administration of
cyclic AMP.
6 Conclusions
1. To our knowledge the administration of a
beta-blocker together with a beta-mimetic
to the mother during labor does not evoke
deleterious side-effects either in mother or the
fetus.
2. The so-called cardiospecific beta-blocker Prac-
tolol, has no cardiospecificity resulting in
different responses in terms of inhibition of the
beta-mimetic effects at metabolic and uterine
levels.
3. It seems important to stress that, at least in
two cases, fetal blood glucose rose under the
effects of the beta-mimetic without any signi-
ficant increase in maternal blood glucose. It
Supports the hypothesis that the increase in
blood glucose observed in the fetus in these
cases is due to a direct effect of the beta-mi-
metic drugs on the fetal metabolic receptors
rather than a ttansplacental transfer of the
maternal glucose.
4. The ability to compete with the beta-mimetic
at receptors of some sites elsewhere in the
body depends on an individual response to
the different sites. It points out the impossibili-
ty of establishing fixed doses and limits the
clinical use of the beta-blocker.
Summary
The effectiveness of the use of beta-mimetic drugs in
obstetrics may be limited by the fact that the Stimulation
of the uterine beta-receptors is not specific and is ac-
companied by the Stimulation of the other beta-receptors
elsewhere in the body. The ideal means of avoiding the
cardiovascular and/or the metabolic effects of these drugs
would be the possibility of obtaining specific stimulators
for the different anatomical locations pf the receptors. But,
up to the present time, nothing indicates a qualitative
differentation among them and, in conseqüence, a specific
uterine betamimetic drug does not exist.
For the purpose of avoiding this difficulty, ESKES et al.
(1965) suggested the use of a beta-blocker'with the aim
of obtaining a cardio-specificity in the blockade.
The purpose of the present study is the search for a dose
of a beta-blocker claimed to be cardio-specific, ef-
fective at the cardiovascular level but without im-
pairing the desired beta-mimetic effect at the uterine
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level. The drugs used were Ritodrine-HCl äs beta-mimetic
and Practolol äs beta-blocker.
The study was carried out in 12 normal patients in labor,
in which the following variables were studied: intraamniotic
pressure, maternal heart rate, maternal electrocardiogram,
fetal heart rate, maternal blood pressure, fetal capillary
pH, maternal venous pH, maternal blood glticose and
fetal blood glucose.
The study was divided into four successive stages, the
characteristics of each one being determined by the sug-
gestions arising from the results obtained in the preceding
one.
The results of the study show that the administration of the
beta-blocker together with the beta-mimetic to the mother
du ring labor does not evoke deleterious side-effects eithet
in the mother or the fetus and that the so-called cardiospeci-
fic beta-blocker Practolol, äs expected, does not have a
cardiospecificity with difTerent responses äs to the
Inhibition of the beta-mimetic effects at metabolic
and uterine levels (Figs. l to 5). The ability to compete
with the beta-mimetic at the receptors of some anatomical
areas depends on an individual response to the different
areas; this points out the impossibility of establishing fixed
doses and limits the clinical use of the beta-blocker.
Finally, from the study of the maternal and fetal blood
glucose (Figs. 6 to 9), it appeared that, at least in some
cases, maternal blood glucose did not change and only the
fetal blood glucose showed the typical beta-mimetic
effect. This fact Supports the hypothesis of a single meta-
bolic response by the fetus to the beta-mimetic treatment.
I. e. the increase in blood glucose in the fetus is due to
a direct effect of the beta-mimetic drug on the fetal
metabolic receptors rather than a transplacental
transfer of the maternal glucose.
Keywords: Beta-blocker, beta-mimetics, (metabolic and cardiovascular effects), glucose, mother, fetus, Practolol, Ritodrine.
Zusammenfassung
Ein Versuch, die kardio-vaskulären und metabo-
lischen Nebenwirkungen beta-mimetischer Mittel
unter der Geburt zu blockieren
Die Wirksamkeit von beta-mimetischen Mitteln in der
Geburtshilfe ist durch den Umstand begrenzt, daß die
Stimulation der Beta-Rezeptoren nicht spezifisch ist und
daß sie mit Stimulation anderer Beta-Rezeptoren im
Körper einhergeht. Im Idealfall könnten die metabolischen
und/oder kardiovaskulären Nebenwirkungen dieser Mittel
vermieden werden, falls spezifische Stimulatoren für die
Rezeptoren in verschiedenen Organen zur Verfügung
ständen. Jedoch ist ein qualitativer Unterschied noch nicht
gefunden worden und ein uterus-spezifisches Beta-Mi-
metikum existiert folglich nicht.
ESKES et al. (1965) schlugen zur Vermeidung dieser
Schwierigkeit vor, einen Beta-Blocker anzuwenden, um
eine herz-spezifische Blockade zu erreichen.
Unsere Arbeit versuchte, eine Dosis für einen angeblich
herz-spezifischen Beta-Blocker zu bestimmen, bei
welcher eine kardiovaskuläre Wirksamkeit bestand,
ohne dabei die erwünschte Wirkung auf den Uterus
zu vermindern. Die angewendeten Mittel waren Rito-
drine-HCl als beta-mimetisches und Practolol als beta-
blockierendes Mittel.
Die Versuche wurden an 12 Patientinnen mit Wehen-
tätigkeit ausgeführt. Die folgenden Meßwerte wurden
bestimmt: Intra-amniotischer Druck, mütterliche Herz-
frequenz, EKG und Blutdruck, fetale Kapillar-pH-Wert
mütterlicher venöser pH-Wert, mütterliche und fetale
Blutglukose.
Die Untersuchung wurde in 4 aufeinanderfolgende Stadien
aufgeteilt, wobei die Bedingungen für die folgende jeweils
durch die Ergebnisse der voraufgehenden Stufe bestimmt
wurden.
Es wurde festgestellt, daß die Verabreichung eines Beta-
Blockers zusammen mit dem beta-mimetischen Mittel an
die Mutter unter der Geburt keinerlei schädliche Ein-
wirkungen auf Mutter oder Kind hatte und daß — wie
erwartet — der angeblich herz-spezifische Beta-Blocker
Practolol keine Herzspezifität aufweist bezüglich
unterschiedlicher Hemmungen der beta-mimetischen
Wirkung auf Stoffwechsel und Uterus (Fig. l—5).
Die Fähigkeit, mit dem beta-mimetischen Mittel an den
Rezeptoren in anderen Organen zu konkurrieren, ist von
der individuellen Reaktion der verschiedenen Orte ab-
hängig; dies zeigt auf, daß es unmöglich ist, bestimmte
Dosierungen festzusetzen und beschränkt den klinischen
Gebrauch der Beta-Blocker.
Schließlich hat es den Anschein beim Verhalten der mütter-
lichen und fetalen Blutglukose (Figs. 6—9), daß — zu-
mindest in Einzelfällen — die mütterliche Blutglukose
sich nicht veränderte und nur der fetale Blutzucker einen
typischen beta-mimetischen Effekt auf wies. Diese Tat-
sache unterstützt die Hypothese einer metabolischen
Einzelreaktion auf die beta-mimetische Behandlung. Der
fetale Blutzuckeranstieg beruht also auf einer Direkt-
wirkung des beta-mimetischen Mittels auf die fetalen
Stoffwechselrezeptoren und nicht auf einer trans-
plazentaren Passage der mütterlichen Glukose.
Schlüsselwörter: Beta-Blocker, Beta-Mimetika, Fet, Herz-Gefäß-System, Mutter, Practolol, Ritodrine, Stoffwechsel.
Resume
Un essai d'elimination des effets secondaires cardio-
vasculaires et m£taboliques dus a l'utilisation des ß-
stimulants au cours du travail
L'efficacite des ß-mimetiques en obstetrique, est souvent
limite par le fait que leur activite sur les /?-r6cepteurs
uterins n'est pas specifique et s'accompagne d'une Sti-
mulation des autres rocepteurs, dissemines dans Forganisme
tout entier. L'idoal, pour eliminer les effets cardiovascu-
laires et motaboliques de ces drogues, serait de stimuler
les jS-r6cepteurs de fagon spocifique et prdfdrentielle, en
J. Pcrinat. Mcd. 2 (1974) 18*
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fonction de leur Situation topographique. Hdlas, jusqu'ä
prosent, rien ne nous permet de penser qu'il existe une
differcnciation qualitative parmi ces rocepteurs et, en
consequence, il nous est impossible de profiter d'une
dventuelle spocificite de l'uterus vis a vis des j8-mim6tiques.
Afin de tourner cette difficulto, ESKES et coll. (1965) sug-
gererent de neutraliser les effets secondaires cardiovascu-
laires des j3-mimetiques en leur associant un /?-bloquant a
action specifique cardiaque.
Le but de ce travail est de determiner la dose de ß-
bloquant ä utiliser dit cardiospecifique afin d'eliminer
les effets secondaires des /5-stimulants sans en supprimer
les effets myorelaxants uterins. Les produits utilises
furent la Ritodrine, comme /?-mimetique, et le Practolol,
comme ß-bloquant.
L'etude fut realisee sur 12 patientes normales en travail.
Les parametres suivant furent etudies: la pression intra-
amniotique, le rythme cardiaque maternel, l'electrocardio-
gramme maternel, le rythme cardiaque foetal, la pression
sanguine maternelle, le pH capillaire foetal, le pH veineux
maternel, les glycemies foetales et maternelles.
L'etude fut divisee en quatre etapes, les caracteristiques de
x chaque etape ulterieure etant determinees en fonction des
resultats obtenus au cours de Tetape precedente.
Les resultats de l'etude montrent que l'administration d'une
association de /?-bloquant et de /?-stimulant ä la femme en
travail, n'entraine d'effets secondaires nocifs ni chez la
mere, ni chez le foetus. Cpmme prevu, le Practolol
(/3-bloquant soi-disant cardiospecifique), n'est pas
cardiospecifique et provoque effects divertes du point
de vue du metabolisme et de la motilite de l'uterus
(Figs. l—5). La capacite qu'ont les ß-mimetiques d'agir
en meme temps, sur les recepteurs de plusieurs sites
topographiques, depend d'urie sensibilite individuelle des
differents sites. Ce fait explique l'impossibilite de deter-
miner les doses utiles et les limites d'utilisation des ß-blo-
quants en clinique courante.
Enfin, de Fetude des glycemies (Figs. 6—9), il apparait
que dans la plupart des cas, la glycemie maternelle ne
change pas, seule la glycemie foetale se modifie sous l'in-
fluence specifique de la substance jS-mimetique. Ce fait
soutient l'hypothese de l'existence d'une reponse foetale
seule, du point de vue metabolique, au traitement ß-
stimulant. Ceci suggere que Paugmentation de la
glycemie foetale est due ä un effet direct de la drogue
sur le metabolisme hydrocarbone du foetus, plutöt
qu'ä un passäge transplacentaire du glucose de la
mere vers le foetus.
Mots-cles: j8-mimetiques (effets metaboliques, efFets cardiovasculaires), ]3-stimulants, glycemie, mere, foetus, Practolol,
Ritodrine.
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